Logo Image
|Articles|April 27, 2022

Pfizer-BioNTech Submits FDA EUA Application for its COVID-19 Booster for Children 5 Through 11 Years Old

The filing included data from their phase 2/3 trial in this pediatric age group.


The 2 companies announced late yesterday that they had had filed an Emergency Use Authorization (EUA) with the Food and Drug Administration (FDA) of a 10-µg booster dose of their COVID-19 vaccine for children 5 through 11 years of age.

The filing was based from the data from their phase 2/3 trial, which the companies reported nearly 2 weeks ago, and showed a 36-fold increase in Omicron neutralizing titers following a third dose of their COVID-19 vaccine.

The study had 140 children, between 5-11 years of age, who received the third dose of the vaccine 6 months after the second shot of the Pfizer-BioNTech COVID-19 vaccine. The companies reported a sub analysis of 30 sera from this study indicated that serum antibodies induced by the booster (third dose) neutralized the Omicron variant with a 36-fold increase in neutralizing antibody titers compared to levels seen after 2 doses of their vaccine. The companies said a robust response was observed regardless of prior COVID-19 infection.

They also said there were no new safety signals.

Currently this vaccine is FDA authorized for the following doses:

Vaccine Primary Series

  • a 2-dose primary series to individuals 5 years of age and older
  • a third primary series dose to individuals 5 years of age and older with certain kinds of immunocompromise

Booster Doses

  • a first booster dose to individuals 12 years of age and older who have completed a primary series with the Pfizer-BioNTech COVID-19 vaccine
  • a first booster dose to individuals 18 years of age and older who have completed primary vaccination with a different authorized or approved COVID-19 vaccine. The booster schedule is based on the labeling information of the vaccine used for the primary series
  • a second booster dose to individuals 50 years of age and older who have received a first booster dose of any authorized or approved COVID-19 vaccine
  • a second booster dose to individuals 12 years of age and older with certain kinds of immunocompromise and who have received a first booster dose of any authorized or approved COVID-19 vaccine

Related to this article

View more
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Read more
FAQ: Ebola Prevention, Treatment and the Chances of a US Outbreak
FAQ: Ebola Prevention, Treatment and the Chances of a US Outbreak
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.
Read more
Measles Update: October 30, 2026
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Read more
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Read more